Floatz Rating
B57/100
Confidence
Indicative
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01524926CT.gov CREATE: Cross-tumoral Phase 2 With Crizotinib | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Clear Cell Sarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Crizotinib (this asset) | European Organisation for Research and Treatment of Cancer - EORTC | P2 | B · 57 |
| Tivantinib | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | P2 | B |
| Cabozantinib | National Cancer Institute (NCI) | P2 | CCC |
| Cobimetinib | Radboud University Medical Center | P2 | CCC |
| Atezolizumab | National Cancer Institute (NCI) | P2 | CCC |
| Vemurafenib | Radboud University Medical Center | P2 | CCC |
| Zoledronate | University of Florida | P1/2 | CCC |
| Cyclophosphamide | St. Jude Children's Research Hospital | P1 | CC |
| Sirolimus | Emory University | P1 | CC |
+11 more in the Clear Cell Sarcoma cohort
Other indications for Crizotinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Anaplastic Large Cell Lymphoma | — | P4 | BBB · 75 |
| Inflammatory Myofibroblastic Tumor | — | P4 | BB · 69 |
| ALK-Positive Anaplastic Large Cell Lymphoma | — | P4 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- TivantinibArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)B
- CabozantinibNational Cancer Institute (NCI)CCC
- CobimetinibRadboud University Medical CenterCCC
- AtezolizumabNational Cancer Institute (NCI)CCC
- VemurafenibRadboud University Medical CenterCCC
Citation
Floatz Terminal. Crizotinib in Clear Cell Sarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/crizotinib-clear-cell-sarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →